Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$65.55M, compared with $15.42M a year earlier. Trailing-twelve-month net change in cash was $55.09M.

Context

  • Net change in cash amounted to 6.4% of revenue in FY2025, up 5.8 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$65.55M or moves back toward the trailing-twelve-month quarterly average of $13.77M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$65.55M-39.9% QoQ
Last fiscal yearDec 2025
$194.52M+907.2% YoY
LTMJun 2026
$55.09M+61.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-525.2%——
1 year+907.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
194.52M USD
Year-over-year change
+907.2%

Net Change in Cash vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +61.2% is the 5th highest of 11, against a peer median of -8.1%.
  • Net change in cash amounts to 1.8% of revenue for AMRX, versus a peer median of 1.9%.
AMRX Competitors
Net Change in Cash for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹2.29B INR+266.1%-54.1%0.7%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$1.49B USD+1640.2%-26.2%8.6%
VTRSViatris Inc.LTM Jun 2026$322.2M USD+191.9%+3.2%2.2%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$286M USD-238.2%-27.7%21.5%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$161.38M USD+304.9%—17.5%
BHCBausch Health Companies Inc.LTM Jun 2026$93.89M USD-91.6%—0.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$55.09M USD+61.2%—1.8%
PRGOPerrigo Company plcLTM Jun 2026$54.9M USD-38.0%-72.2%1.3%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$11.84M USD-35.5%-14.5%1.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$8.7M USD-88.2%+16.0%1.3%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$4.1M USD+19.2%-3.6%9.8%
Peer median (excluding AMRX) —-8.1%-20.4%1.9%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income10.62M(254.79M)(48.72M)(73.88M)72.06M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
Deferred Income Tax00000
Stock-Based Compensation031.85M26.82M27.77M31.95M
Change in Working Capital(133.59M)(59.95M)(47.19M)(4.07M)(204.52M)
Accounts Receivables(16.31M)(79.07M)125.8M(162.16M)(120.57M)
Inventory(49.02M)(102.4M)(126.18M)(130.53M)(87.03M)
Accounts Payables(43.93M)109.57M(94.45M)235.14M21.32M
Other Working Capital(24.34M)11.95M47.64M53.48M(18.23M)
Other Non-Cash Items131.38M107.81M185.26M109.08M216.93M
Operating Cash Flow241.82M65.1M345.58M295.1M339.99M
Capital Expenditures(47.73M)(90.6M)(69.19M)(74.99M)(70.06M)
Acquisitions (Net)(141.54M)(84.71M)011.99M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.21M)(40.8M)(22.39M)(14.65M)(42.2M)
Investing Cash Flow(194.18M)(174.31M)(69.19M)(63M)(112.26M)
Debt Repayment(79.18M)(38.27M)22.65M(185.12M)26.27M
Common Stock Issued853K0001.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(59.8M)(68.35M)(235.23M)(26.67M)(59.76M)
Financing Cash Flow(138.12M)(106.62M)(212.57M)(211.79M)(31.53M)
Effect of Forex Changes102K(5.68M)65K(999K)(1.68M)
Net Change in Cash(90.38M)(221.51M)63.88M19.31M194.52M
Free Cash Flow194.09M(25.5M)276.39M220.11M269.93M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.